India Denies Rice Dumping Allegations, Expert Says Demand Remains Robust Despite High Tariffs

Ensysce Biosciences has initiated enrollment in its pivotal Phase 3 trial of PF614, a next-generation opioid engineered for potent pain relief with built-in abuse protection. The trial aims to demonstrate PF614's efficacy and safety in treating moderate to severe pain after surgery, while incorporating a chemical mechanism to reduce the risk of abuse. This milestone marks a significant step towards commercialization for Ensysce's lead product candidate.